XyloCor and SmartCella enter into license agreement for use of the Extroducer to administer novel gene therapy XC001 to the heart

The Extroducer® Infusion Catheter System® enables local delivery of XC001 to the heart without the need for surgery.XC001 has achieved positive Phase 1/2 results in the EXACT Trial validating its transformative potential for treatment of refractory angina in patients who have exhausted available treatment options and have a debilitating quality-of-life.
610-541-2056

Media Contact:
Mike Beyer
Sam Brown Inc. Healthcare Communications, mikebeyer@sambrown.com
312-961-2502

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/smartcella-holding-ab/r/xylocor-and-smartcella-enter-into-license-agreement-for-use-of-the-extroducer-to-administer-novel-ge,c4013444

The following files are available for download:

https://mb.cision.com/Main/21365/4013444/2909969.pdf

Press release XyloCor SmartCella 240710 Eng

https://news.cision.com/smartcella-holding-ab/i/extroducer,c3318757

Extroducer

 

View original content:https://www.prnewswire.co.uk/news-releases/xylocor-and-smartcella-enter-into-license-agreement-for-use-of-the-extroducer-to-administer-novel-gene-therapy-xc001-to-the-heart-302193539.html

en | boerse | 67942010 |